Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review
Background. Migraine is one of the most common types of headache, and it is the second most common cause of neurological disorders, with an annual prevalence of about 15% of the population. This study aimed to evaluate the effect of BoNT-A on the duration and intensity of migraine attacks. In additi...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Pain Research and Management |
| Online Access: | http://dx.doi.org/10.1155/2022/3284446 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562216531918848 |
|---|---|
| author | Negar Shaterian Negin Shaterian Aref Ghanaatpisheh Farnaz Abbasi Sara Daniali Maryam Jalali Jahromi Mohammad Sadegh Sanie Amir Abdoli |
| author_facet | Negar Shaterian Negin Shaterian Aref Ghanaatpisheh Farnaz Abbasi Sara Daniali Maryam Jalali Jahromi Mohammad Sadegh Sanie Amir Abdoli |
| author_sort | Negar Shaterian |
| collection | DOAJ |
| description | Background. Migraine is one of the most common types of headache, and it is the second most common cause of neurological disorders, with an annual prevalence of about 15% of the population. This study aimed to evaluate the effect of BoNT-A on the duration and intensity of migraine attacks. In addition, we investigated the effective injection sites. Methods. According to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines, we searched online databases, including Web of Science, PubMed, EMBASE, Scopus, Cochrane Library, ProQuest, ClinicalTrials.gov, and Google Scholar from 2011 to 2021. Results. A total of 24 articles were included in the study. The use of BoNT-A in individuals suffering from chronic migraine (CM) decreases the frequency of migraine attacks per month, pain intensity, medication use, emergency visits, and migraine-related disabilities. The BoNT-A was well tolerated and leads to improved performance and better quality of life (QoL). Overall, treatment with BoNT-A in adults with CM is beneficial. In addition, the use of BoNT-A in individuals with vestibular migraine (VM) reduces the frequency of migraines and brings about the improvement of disability status caused by migraine headaches. Meanwhile, the use of BoNT-A reduces the frequency of migraine attacks per month among individuals with chronic refractory migraine (CRM). Conclusions. The use of BoNT-A is a low-cost option for the treatment of various kinds of migraines, including chronic, episodic, unilateral, and vestibular types. BoNT-A can reduce the frequency of migraine attacks per month and diminish the severity of pain. |
| format | Article |
| id | doaj-art-c5e147c6acc24849aa34db6963d093c8 |
| institution | Kabale University |
| issn | 1918-1523 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pain Research and Management |
| spelling | doaj-art-c5e147c6acc24849aa34db6963d093c82025-02-03T01:23:13ZengWileyPain Research and Management1918-15232022-01-01202210.1155/2022/3284446Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic ReviewNegar Shaterian0Negin Shaterian1Aref Ghanaatpisheh2Farnaz Abbasi3Sara Daniali4Maryam Jalali Jahromi5Mohammad Sadegh Sanie6Amir Abdoli7Zoonoses Research CenterSchool of Nursing & MidwiferyStudent Research CommitteeStudent Research CommitteeStudent Research CommitteeResearch Center for Noncommunicable DiseasesResearch Center for Noncommunicable DiseasesZoonoses Research CenterBackground. Migraine is one of the most common types of headache, and it is the second most common cause of neurological disorders, with an annual prevalence of about 15% of the population. This study aimed to evaluate the effect of BoNT-A on the duration and intensity of migraine attacks. In addition, we investigated the effective injection sites. Methods. According to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines, we searched online databases, including Web of Science, PubMed, EMBASE, Scopus, Cochrane Library, ProQuest, ClinicalTrials.gov, and Google Scholar from 2011 to 2021. Results. A total of 24 articles were included in the study. The use of BoNT-A in individuals suffering from chronic migraine (CM) decreases the frequency of migraine attacks per month, pain intensity, medication use, emergency visits, and migraine-related disabilities. The BoNT-A was well tolerated and leads to improved performance and better quality of life (QoL). Overall, treatment with BoNT-A in adults with CM is beneficial. In addition, the use of BoNT-A in individuals with vestibular migraine (VM) reduces the frequency of migraines and brings about the improvement of disability status caused by migraine headaches. Meanwhile, the use of BoNT-A reduces the frequency of migraine attacks per month among individuals with chronic refractory migraine (CRM). Conclusions. The use of BoNT-A is a low-cost option for the treatment of various kinds of migraines, including chronic, episodic, unilateral, and vestibular types. BoNT-A can reduce the frequency of migraine attacks per month and diminish the severity of pain.http://dx.doi.org/10.1155/2022/3284446 |
| spellingShingle | Negar Shaterian Negin Shaterian Aref Ghanaatpisheh Farnaz Abbasi Sara Daniali Maryam Jalali Jahromi Mohammad Sadegh Sanie Amir Abdoli Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review Pain Research and Management |
| title | Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review |
| title_full | Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review |
| title_fullStr | Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review |
| title_full_unstemmed | Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review |
| title_short | Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review |
| title_sort | botox onabotulinumtoxina for treatment of migraine symptoms a systematic review |
| url | http://dx.doi.org/10.1155/2022/3284446 |
| work_keys_str_mv | AT negarshaterian botoxonabotulinumtoxinafortreatmentofmigrainesymptomsasystematicreview AT neginshaterian botoxonabotulinumtoxinafortreatmentofmigrainesymptomsasystematicreview AT arefghanaatpisheh botoxonabotulinumtoxinafortreatmentofmigrainesymptomsasystematicreview AT farnazabbasi botoxonabotulinumtoxinafortreatmentofmigrainesymptomsasystematicreview AT saradaniali botoxonabotulinumtoxinafortreatmentofmigrainesymptomsasystematicreview AT maryamjalalijahromi botoxonabotulinumtoxinafortreatmentofmigrainesymptomsasystematicreview AT mohammadsadeghsanie botoxonabotulinumtoxinafortreatmentofmigrainesymptomsasystematicreview AT amirabdoli botoxonabotulinumtoxinafortreatmentofmigrainesymptomsasystematicreview |